Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results | 7 November 2025(3 announcements)

Torrent Pharmaceuticals reported Q2 FY2026 consolidated revenue of ₹3,302 crores, up 14% YoY, with net profit of ₹591 crores, growing 30% YoY. Half-year revenue reached ₹6,480 crores (13% growth) and net profit ₹1,139 crores. Operating margins improved to 32.8% with strong geographic performance: India +12%, Brazil +21%, US +26%. The company proposed acquiring J.B. Chemicals & Pharmaceuticals for approximately ₹11,917 crores, pending regulatory approval. Total assets grew to ₹15,515 crores; debt-to-equity improved to 0.31.

Torrent Pharmaceuticals Limited disclosed an audio recording of its Q2 FY2026 (half-year ended 30th September 2025) analyst conference call on its investor website. The filing is a regulatory notification under SEBI Listing Obligations, providing access to management commentary on financial results. Specific financial metrics were not detailed in this disclosure document.

Torrent Pharmaceuticals reported consolidated revenue of ₹3,302 crores for Q2 FY2025-26, growing 14% YoY from ₹2,889 crores. India revenue rose 12% to ₹1,820 crores, while international markets showed stronger growth: United States 26% to ₹337 crores, Brazil 21% to ₹318 crores, and Germany 5% to ₹303 crores. Half-year revenue reached ₹6,480 crores, up 13% YoY.